Dr. Luke Philip Dreisbach, MD

Dr. Dreisbach practices at Desert Hematology-Oncology Medical Group Inc in Rancho Mirage, California.

Dr. Dreisbach's NPI, 1831109792, was assigned on August 9, 2006. Dr. Dreisbach graduated from McGovern Medical School in 1994. Dr. Dreisbach's California license number on file is A70978.

Dr. Dreisbach's primary practice is Desert Hematology-Oncology Medical Group Inc, at 39800 Bob Hope Dr, Rancho Mirage, CA 92270 in Riverside County. The practice phone is (760) 568-3613.

Dr. Dreisbach's primary practice is Desert Hematology-Oncology Medical Group Inc in Rancho Mirage, California. Dr. Dreisbach is also affiliated with Eisenhower Health. The medical group on file is Desert Hematology Oncology. Dmand AI also links Dr. Dreisbach to 2 more hospitals, 1 group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dreisbach practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Dreisbach's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Dreisbach is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Dreisbach's licenses on file in 3 states: California, Arizona and Wisconsin.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, colorectal cancer, immune deficiency disease, lung cancer and lymphoma among the conditions Dr. Dreisbach treats.

CMS data shows 777,669 Medicare services from Dr. Dreisbach across 80 procedure codes in 2024, for 1,441 Medicare patients. Medicare paid $10,874,669 for them.

CMS counts 1,441 Medicare patients who saw Dr. Dreisbach in 2024. The largest group is 75 to 84, with 643 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 12% are also on Medicaid. Their average risk score is 2.01, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dreisbach's median patient age at 72, with 58% women.

In 2024, Dr. Dreisbach wrote 1,785 Medicare Part D claims for 341 patients. 65% of them were for generic drugs. CMS names the drug for 1,475 of them, across 41 drugs with 11 or more claims each, at $7,582,441 in total drug cost. In 2023, CMS named 1,221 claims across 37 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Dreisbach for performance year 2024, reported as part of a group. Dr. Dreisbach accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dreisbach as offering telehealth.

Dmand AI links 7 papers to Dr. Dreisbach, published from 2011 to 2020. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Fatal Outcome and Neoplasm Metastasis. Dr. Dreisbach's most frequent co-authors are Asher A. Chanan-Khan, MD, Joseph I. Clark, MD and Allen L. Cohn, MD.

Dmand AI links Dr. Dreisbach to 10 clinical trials, 4 of them phase 3 studies. 6 are still active or recruiting. Conditions studied include Neoplasm Metastasis, Neoplastic Processes and Breast Neoplasms. ImmunityBio, Inc. sponsors the most, 2. Open Payments lists research payments to Dr. Dreisbach that name 2 trials.

CMS Open Payments shows 1,462 general payments to Dr. Dreisbach from 100 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 99% of the total. Novartis Pharmaceuticals Corporation paid the most, $2,547. It also lists 6 research payments totaling $1,855 from 2023 to 2024, naming 2 clinical trials.

Dr. Dreisbach graduated from McGovern Medical School in 1994.

Dr. Dreisbach is in network with 12 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.